Agenus' Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer
Data presented at plenary session of Society of Gynecologic Oncology Meeting Patients treated suffered from platinum resistant/refractory ovarian cancer Previous PD-1/CTLA-4... | March 27, 2023
Source: marketscreener.com